Agreements reached under this partnership
Business alliance- 1
A system for supplying medical institutions nationwide by leveraging the pharmaceutical distribution network of the Toho Holdings Group, to achieve the smooth market launch and stable supply of Stemchymal after obtaining marketing approval
- 2
Discuss and consider a distribution system and other arrangements suited to the characteristics of regenerative medicine products
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on financial results is currently immaterial, but over the medium to long term, we believe it will contribute to improving the corporate value of our group. If the need for timely disclosure arises, we will promptly make an announcement.
| Item | Details |
|---|---|
| Name of alliance partner | ReproCELL Incorporated |
| Alliance partner's business activities | ① Research support business: manufacture and sale of iPS cell-related research reagents; provision of drug discovery support services; provision of biological samples; provision of genetic analysis services ② Medical business: contract clinical testing services; development of regenerative medicine products |
| Alliance partner's location | 3-8-11 Shinyokohama, Kohoku-ku, Yokohama, Kanagawa Prefecture |
| Alliance partner's capital | ¥2,720 million (as of the end of March 2026) |
| Type of alliance | Business alliance |
| Details of the alliance | A system for supplying medical institutions nationwide by leveraging the pharmaceutical distribution network of the Toho Holdings Group, to achieve the smooth market launch and stable supply of Stemchymal after obtaining marketing approval, Discuss and consider a distribution system and other arrangements suited to the characteristics of regenerative medicine products |
| Contract Date | 17 September 2026 |
| Impact on Business Performance | The impact of this matter on financial results is currently immaterial, but over the medium to long term, we believe it will contribute to improving the corporate value of our group. If the need for timely disclosure arises, we will promptly make an announcement. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To achieve the smooth market launch and stable supply of Stemchymal® after obtaining marketing approval, together with ReproCELL Incorporated, and to establish a system for stable supply of the product to medical institutions nationwide.